Kappac Pharma Peer Comparison

BSE: 506938

₹112.85

₹-5.90 (-4.97%)

As on 06-Jan-2015IST

Market cap

₹341 Cr

Revenue (TTM)

₹0 Cr

P/E Ratio

--

P/B Ratio

9

Div. Yield

0 %

Edit

	Kappac Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Market cap (₹ Cr)	341	36,196	28,240	27,294	28,644
Revenue (₹ Cr)	--	3,564	1,936	1,462	9,205
Net Profit (₹ Cr)	-2.20	414.00	288.22	387.35	-371.81
Net Margin (%)	101.15	11.23	14.79	26.01	-3.93
RoE (%)	-6.25	8.38	29.77	25.18	-3.85
Price to Earnings	--	88.50	97.98	70.67	--
Price-To-Book	8.97	7.19	21.04	15.82	3.58

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Kappac Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Operating Revenue	--	4,830.36	41.58	76.11	--
Total Income	0.00	4,914.64	41.73	76.68	--
Total Expenditure	0.08	3,850.53	30.00	69.99	--
EBITDA	-0.08	979.83	11.59	6.12	--
Depreciation	--	139.92	3.35	0.80	--
EBIT	-0.08	839.91	8.24	5.32	--
Interest	0.00	83.35	2.34	1.58	--
Other Income	--	84.28	0.14	0.56	--
Exceptional Items	--	49.83	--	--	--
Profit before Tax	-0.08	890.67	6.04	4.31	--
Provision for Tax	--	47.88	1.54	1.44	--
Profit after Tax	-0.08	842.79	4.50	2.86	--

Liabilities (₹ Cr)

	Kappac Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Shareholder's Funds	38.11	3,581.47	44.83	10.77	--
Minority Interest	--	136.17	--	--	--
Non-Current Liabilities	0.00	1,161.18	10.36	1.29	--
Current Liabilities	0.50	1,743.20	21.34	26.33	--
Total Liabilities	38.61	6,622.02	76.53	38.71	--

Assets (₹ Cr)

	Kappac Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Non-Current Assets	8.31	3,266.10	51.75	7.38	--
Current Assets	30.30	3,355.92	24.78	31.01	--
Total Assets	38.61	6,622.02	76.53	38.71	--
Total Debt*	0.49	1,906.08	21.09	12.17	--
Net Current Assets	29.80	1,612.72	3.44	4.68	--
Contingent Liabilities	--	267.40	4.70	--	--

Cashflow (₹ Cr)

	Kappac Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Cash From Operating Activities	4.19	1,476.29	6.29	-0.21	--
Cash Flow from Investing Activities	-5.42	-851.62	-5.46	-2.00	--
Cash from Financing Activities	-4.24	-601.32	-0.58	2.17	--
Net Cash Inflow / Outflow	-0.04	23.35	0.25	-0.04	--

Ratios

Profitability Ratios

	Kappac Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
ROCE (%)	-0.27	18.98	13.38	29.97	--
ROE (%)	-0.27	30.04	19.08	30.26	--
ROA (%)	-0.26	13.36	6.16	8.85	--
EBIT Margin (%)	--	22.03	28.21	8.78	--
Net Margin (%)	--	17.15	10.78	3.74	--
Cash Profit Margin (%)	--	20.32	18.86	4.81	--

Growth Ratios

	Kappac Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Revenue Growth (%)	--	-13.89	12.11	37.10	--
EBIT Growth (%)	-0.28	-49.66	21.82	30.95	--
Net Profit Growth (%)	0.08	-46.64	58.36	39.55	--
EPS Growth (%)	21.43	-56.04	58.36	39.55	--
Book Value Growth (%)	59.47	36.37	21.09	32.03	--

Valuation Ratios

	Kappac Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Price / Earnings	0.00	6.59	0.00	0.00	--
Price / Book Value	54.69	1.55	0.00	0.00	--
Dividend Yield (%)	0.00	2.19	--	--	--
EV/EBITDA	0.00	5.73	3.52	2.02	--
Market Cap (₹ Cr)	--	5,016.58	0.00	0.00	--

Solvency Ratios

	Kappac Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debt to Equity	0.01	0.54	0.47	1.13	--
Short term debt to equity ratio	0.01	0.06	0.23	0.84	--
Current Ratio	60.78	1.93	1.16	1.18	--
Quick Ratio	60.78	1.36	1.11	0.75	--
Interest Coverage	-3,866.11	11.69	3.58	3.73	--

Operating Efficiency Ratios

	Kappac Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debtors to sales (%)	--	9.96	33.85	17.81	--
Asset Turnover	0.00	0.77	0.57	2.35	--
Receivable days	--	54.33	106.93	58.46	--
Inventory Days	--	77.43	10.49	41.85	--
Payable days	--	120.43	213.33	91.25	--
Cash Conversion Cycle	--	11.32	-95.91	9.06	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly